MANCHESTER, UK, May 30, 2012 – CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today reported advances in the company’s regulatory and market initiatives for its Nicadex™ electronic inhaler nicotine replacement therapy (NRT) product and Intellicig® electronic cigarettes.

4-Antibody and Evotec launch a new high-content screening platform for early antibody functionality testing

Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
for $650 million in cash plus a potential $50 million milestone payment

CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today announced that Tim Byrne has been appointed Chief Financial Officer.

Cellnovo today announced both the launch of the world’s only mobile-connected diabetes management system, and the start of the largest usability trial ever to investigate insulin pump technology for patients with type 1 diabetes.

Linda Robson's comment as she was handed an Intellicig to try on the 'This Morning' show on ITV said it all; "Fantastic!" she exclaimed.

Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies

Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases

CNC Combining Its Broad Expertise in Smoking Cessation and Electronic Cigarette Technology to Offer Smokers New Medical Options to Reduce Harm and Help Them Quit

Funds and team growth for developing a breakthrough medical system for mapping of atrial fibrillation